Biosearch Life, Camino de Purchil 66, 18004, Granada, Spain.
Nursing home "Residencia de Mayores Claret", Granada, Spain.
Eur J Nutr. 2019 Feb;58(1):83-90. doi: 10.1007/s00394-017-1573-1. Epub 2017 Nov 9.
Elderly people are particularly vulnerable to seasonal influenza. Therefore, vaccination is strongly recommended. However, the vaccine efficacy is lower in the elderly, owing to immunosenescence. The objective of the present study was to evaluate the ability of the probiotic strain Lactobacillus coryniformis K8 CECT5711 to enhance the immune response to the influenza vaccine in the elderly and to assess the effects on symptoms related to respiratory infections.
A randomized, double-blind, placebo-controlled trial was conducted between November 2015 and April 2016. A total of 98 nursing home residents, more than 65 years of age were randomly assigned to receive L. coryniformis K8 CECT5711 (3 × 10 CFU/day) or a placebo for 2 weeks before influenza vaccination. The primary outcome was the percentage of seroconversion. The secondary outcomes were the incidence of influenza-like illness (ILI) and respiratory symptoms associated with respiratory infections during the 5-month follow-up period. The serum cytokine and immunoglobulin levels were also evaluated.
The percentage of responders to vaccination was higher in the probiotic group than in the control group (p = 0.036). L. coryniformis ingestion was associated with a significantly lower incidence of respiratory symptoms commonly associated with respiratory infections (p = 0.007) and lower consumption of analgesics (p = 0.008).
The administration of L. coryniformis K8 CECT5711 to an elderly population increased the immune response against the influenza vaccine and decreased symptoms associated with respiratory infections. Probiotic administration may be a natural and safe strategy to improve the efficacy of vaccines and to protect against common respiratory infections in susceptible populations.
老年人特别容易受到季节性流感的影响。因此，强烈建议接种疫苗。然而，由于免疫衰老，老年人的疫苗效力较低。本研究的目的是评估益生菌菌株 Corynebacterium lactis K8 CECT5711 增强老年人对流感疫苗免疫反应的能力，并评估其对与呼吸道感染相关症状的影响。
这是一项在 2015 年 11 月至 2016 年 4 月期间进行的随机、双盲、安慰剂对照试验。共有 98 名居住在养老院的老年人（年龄超过 65 岁）被随机分配接受 Corynebacterium lactis K8 CECT5711（3×10 CFU/天）或安慰剂，在流感疫苗接种前服用 2 周。主要结局是血清转化率的百分比。次要结局是在 5 个月的随访期间发生流感样疾病（ILI）和与呼吸道感染相关的呼吸道症状的发生率。还评估了血清细胞因子和免疫球蛋白水平。
益生菌组的疫苗接种应答率高于对照组（p=0.036）。摄入 Corynebacterium lactis 与呼吸道感染相关的呼吸道症状发生率显著降低（p=0.007）和镇痛药消耗减少（p=0.008）相关。
向老年人群体中给予 Corynebacterium lactis K8 CECT5711 可增强对流感疫苗的免疫反应，并减少与呼吸道感染相关的症状。益生菌的使用可能是一种自然且安全的策略，可以提高疫苗的疗效，并保护易感人群免受常见的呼吸道感染。
